INO PDUFA Date: INO-3107 DNA Updated August 19, 2026 ยท next FDA decision on the calendar FDA decision (PDUFA) target Oct 30, 2026 · Inovio Pharmaceuticals · Recurrent respiratory papillomatosis (RRP) BLA
Key facts FDA PDUFA target date 2026-10-30
Drug / candidate INO-3107 DNA
Indication Recurrent respiratory papillomatosis (RRP) BLA
Company Inovio Pharmaceuticals
Market-cap tier Micro
New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs .
See the full 2026 PDUFA calendar → All October 2026 PDUFA dates → FAQ When is the INO PDUFA date? The FDA PDUFA target date for INO (Inovio Pharmaceuticals) is 2026-10-30 for INO-3107 DNA. Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is INO's drug INO-3107 DNA? INO-3107 DNA is Inovio Pharmaceuticals's candidate under FDA review for Recurrent respiratory papillomatosis (RRP) BLA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.